ERBB2 and breast carcinoma: According to recent guidelines, the administration of adjuvant chemotherapy drugs targeting ER, PR, and HER-2 has been shown to significantly enhance the survival rates of individuals with breast cancer.[47,48] It is widely acknowledged that multi-omic analysis surpasses single-gene expression analysis in terms of efficacy.